Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Two new directors with excellent investment management experience will send the stock higher and higher with the advent of these new processes
7/11 Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dr. Eugene Durenard and Mr. Ted Murphy have joined the Board of Directors of Co-Diagnostics, and will serve on the Board’s Compensation and Corporate Governance/Nominating Committees and Audit Committees as independent directors.
Dr. Durenard brings a thorough multi-asset class investment and entrepreneurial experience spanning 20 years to the Board of Directors. He is the founder and CEO of Hyperbolic Holdings, a Swiss-based holding, management consulting and investment advisory company specialized in healthcare since February 2018; co-founder and CIO of Healthcare Impact Holdings, an investment fund specialized in later-stage healthcare private ventures since May 2018; co-founder and trustee of Healthcare Impact Foundation, a charitable organization designed to sustainably fund translation of innovation in life sciences since September 2017; co-founder of Global Better Health, a platform designed to provide scientifically-based corporate wellness and preventive programs since December 2018; and an advisor to and Managing Director of the Stetson Family Office since September 2016. Dr. Durenard received his PhD in Mathematics at Harvard in 1995 before beginning his career with Salomon Brothers in London.
Mr. Murphy has been senior partner in a private investment firm from June 1999 to the present. His duties have included investment analysis of various types of investment projects in health care, real estate and financial services. Mr. Murphy serves on the board of directors of three Canadian publicly reporting companies that have interests in various industries.
This is a great time to BUY as there is no volume related this BIG downturn. Also SRUTF sold shares to their big investor at $.75 each — that should be the minimum price going forward for any long-term investor Ie Oct 2019.
Also I can’t wait for second-quarter to be released as well as October 2019 so this Stock can show it’s true GREEN colors
16.9% short on 320 million shares outstanding is 54 million shares that need to cover
Average trade during the last 10 days was 4.5 million. They’ve only traded 8 million shares today so far.
I estimate 5 times normal volume or 25 million shares to be traded today
Prices going UP today.
Also Analyts will update their revenue projections and they will come out with some new HIGHER price targets later this week
Happy Week to all longs !!
Good News!
Plus CBD balm for sale in Wegmans Fairfax county Virginia near DC. Number of stores and sales sb greatly increased in 2Q
Wegmans is a huge grocery chain
This is excellent news
because once it sells out ( they probably already have the buyers) the stock price will move up to six dollars per share and beyond
Agree with your near term Revenue estimate of $140 million but your valuation is too conservative. Many more avenues of revenue increases based on the needs of population with FDA and EU Approval in hand
Also you presume Price to Sales ratio of 1:1 - 140 million Mkt cap / 140 million Sales divided by 6 million shares outstanding is $23 per share.
P to S of 3to1 ( very reasonable) is more like $60+ per share —current is 5to1
Also the gross profit margin is quite excellent at about 50% so earnings to follow sales
This is an excellent BUYOUT candidate for medical device company - it will not last long given the high TAM (total addressable market)
Needs.
Great video on the use of CBD oil for health benefits – plus CBD oil is featured
https://hoiabc.com/news/2019/02/08/cbd-oil-local-users-saying-it-helped-them-push-pills-aside/
CV Sciences Price Target Announced at $9.00/Share by Roth Capital -
copied from News link
Great News!! Link please
Vote No for Evergreen
They have plenty of shares and options to award for existing and future employees
Senior management last year each made $700,000 + to $1.5 ( Mona III) for about six people not including Mona jr.
employees currently own approximately 10% of the company today
I am a former officer at a Berkshire Hathaway company and the way incentive bonuses work there and should work at small companies is performance based on annual targets - say 35 to 50% of qtr over qtr sales growth for x percent bonus.
What are the performance fees targets for the basis of an award for an associates?
Management should stoke the sales so that the value of the company will go up and shareholders for reap the benefit for employees as we
There’s no reason to increase the stock awards by 4 million shares per year plus unless performance warrants it
Vote NO on Evergreen
until Mgmt makes qtr over qtr significant
Sales increases
or 80% price improvement
CVSI Volume was 150% of the last 10 days daily average confirming the excellent price increase today
Vandelay wrong again
Volume of 1 million shares was150% of the last daily average
Long CVSI
Correction October 2019 for Canada beverages not 2020
Anticipate SRUTF targeted price of $1 plus on Moosehead JV deal
As comparison
HEXO went up 40% from 5 to 7 in short order, after announcing their JV with Molson -
Do your own due diligence
Is there any links for theMorinda conference call for tonight at 8 PM CST?
Who is in the conference call?
Never mind I think it’s tomorrow Friday at 8 PM
Does anyone have the link to the Morinda conference call at 7 PM?
Thanks Rafun
Exciting!!
Please Show calculations for one of these estimates -Thanks
June 11th
VOTE NO ON Evergreen
IF Execs are performing options can be added annually with vote of shareholders
AMEN
Sec reporting requirement I believe are
Purchases greater than 5% are required to be reported on 13 D
45 days after the end of the quarter
Other reporting rules are accelerated if the ownership goes above 10%
Consequently a company can only buy about 10% before any accumulation is well known and they would “still have to pay up” to control the company. Also I believe on a buyout they would want to control more than 51%
Also there were about 36 million shares of shorts out there 15 days ago
Early sellers will not get the value of to $60-$80 a share that it will ultimately take to purchase a significant ownership of the company
Where did you see the 23 million Dollar number?
Standards of care update for diabetes excerpt
Section 10 was updated based on the outcome of Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT), which determined the addition of icosapent ethyl to statin therapy for patients with high triglyceride levels reduced cardiovascular events. The Standards of Care now include a recommendation that icosapent ethyl be considered for patients with diabetes and atherosclerotic cardiovascular disease (ASCVD) or other cardiac risk factors on a statin with controlled LDL-C, but with elevated triglycerides (135-499) to reduce cardiovascular risk.
Correction —that is News from 3/1 not 3/8 - so not related
Not sure I saw this posted. But Friday’s increase may have been partly related to the certification of CSI by the US Hemp authority and CV Sciences, Inc. Appoints Dr. Douglas MacKay as Senior Vice President of Scientific and Regulatory Affairs
https://m.benzinga.com/article/13278756?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+benzinga+%28Benzinga+News+Feed%29
Good News!! For Eontec & LQMT
Eontec is up ~60% in the last 30 days to 11.32
With 64 million shares the volume last night which is eight times average volume
https://finance.yahoo.com/quote/300328.SZ?p=300328.SZ
I saw the CNBC Bart’s interview as well and can confirm her comments on the technology comparison 20 years ago
Great News —If you are able to copy and past some of the report - please do so
Last qtr sales annualized is 52 mil so 81 mil is 60% higher which is huge and matches the 8 PT which is also 60% up
Plus nasdaq uplist not yet factored in
OUTPERFORM and $8 Price Target is good for the near term price:)
Hi Joshuaeyu
Is LQMT foldable?
This is great news as this will be the path to NASDAQ up listing within a short time period
Something is Brewing- M&A?
PFE 2/15/19 traded 25,000 ATM 43/44 calls
Thanks KevGee
Something is Brewing- M&A?
PFZ 2/15/19 traded 25,000 ATM 43/44 calls
Correction PFZ dang spell checker :)